NCT03476603 Bariatric Surgery and Pharmacokinetics of Irbesartan
| NCT ID | NCT03476603 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Norwegian University of Science and Technology |
| Condition | Obesity, Morbid |
| Study Type | OBSERVATIONAL |
| Enrollment | 12 participants |
| Start Date | 2016-11-02 |
| Primary Completion | 2026-10 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on irbesartan are investigated.
Eligibility Criteria
Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.